Adrenocortical Carcinoma

Search Trials
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma
Status:
Active, not recruiting
Last Changed:
Apr 25, 2022
First Changed:
Apr 25, 2022
Disease(s):
Adrenocortical Carcinoma
Intervention(s):
Mitotane
First-in-human Evaluation of [18F]CETO
Status:
Completed
Last Changed:
May 4, 2022
First Changed:
May 4, 2022
Disease(s):
Primary Aldosteronism Due to Aldosterone Producing Adenoma
Intervention(s):
F18CETO
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Status:
Recruiting
Last Changed:
Jun 1, 2022
First Changed:
Feb 14, 2022
Disease(s):
Neuroendocrine Tumors
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Status:
Recruiting
Last Changed:
Jun 30, 2022
First Changed:
May 4, 2020
Disease(s):
Adrenocortical Carcinoma
Intervention(s):
RelacorilantPembrolizumab
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
Status:
Not yet recruiting
Last Changed:
Nov 16, 2021
First Changed:
Sep 5, 2021
Disease(s):
Adrenocortical Carcinoma
Intervention(s):
Pembrolizumab / Lenvatinib

Connect. Empower. Inspire.